“Due to the heterogeneity of methods, it was not possible to carry out meta-analytic evaluations and only qualitative evaluations were feasible.”
Mapping the Clinical Trial Landscape for Cannabinoids in Neurology: A Registry-Based Systematic Review
The review highlights the broad therapeutic potential of cannabinoids in neurology, with promising results in symptom management for conditions like Multiple Sclerosis and Fibromyalgia. However, the lack of standardized study protocols, dosing, and outcome measures presents challenges for broader clinical implementation.
Cannabis and Mental Health: It’s Not Just About ‘Cannabis’
It is likely more appropriate to view cannabis use as a contributing factor to a condition with a multifactorial etiology (e.g., genetic predisposition, use of other drugs, familial and social factors), or the result of individuals having a shared vulnerability to psychosis and cannabis use.
Endocannabinoid System Research: Cannabinoids in Pediatrics
Clinical Takeaway Cannabinoids have been studied across a wide range of pediatric medical conditions, with evidence drawn from both interventional trials and real-world observational data. The current body of research captures both...
Cannabis and the Heart and Vessels: What the Science Actually Says
Although existing literature suggests a direct role of cannabinoids in the pathogenesis of atherosclerosis, the correlation between cannabinoids and other vascular diseases was only reported in some case series or observational studies, and its role and precise mechanisms remain unclear.
Cannabinoids Show Short-Term Promise for Sleep Apnea, But Evidence Remains Too Thin for Clinical Use
Eight of nine total studies reported statistically significant, positive OSA outcomes due to cannabinoid therapy including reductions in the apnea hypopnea index and improvements in patient-reported daytime sleepiness scales. Between 70% and 80% of study participants reported neuropsychiatric and gastrointestinal adverse events attributable to cannabinoids.
Opioids and Cannabinoids for Neurologic Pain: What Neurologists Need to Know in 2024
Subsequent studies documented how the tapering and discontinuation of long-term opioid therapy was correlated with illicit opioid use, emergency department visits and opioid-related hospitalizations, mental health crises and overdose events, and increased risk of death from suicide or overdose.
Cannabinoids Appear Generally Safe in Adults Over 50, But Evidence Is Limited and Heterogeneous
Although cannabinoid-based medications were generally safe and acceptable to adults aged over 50 years, these estimates are limited by the lack of a control condition and considerable heterogeneity. Nevertheless, they complement and are consistent with comparable evidence from randomised controlled trials.
Cannabinoids Show Modest Promise for Cancer-Related Appetite Loss in Older Adults, but Evidence Remains Thin
Cannabinoids offer promise in enhancing the quality of life for older individuals with active neoplastic disease. However, to establish comprehensive guidelines, further research with larger sample sizes is essential.
Therapeutic potential and pharmacological mechanisms of cannabinoids in alleviating chemotherapy-induced organ toxicity and adverse effects.
Chemotherapeutic agent-induced organ toxicities, including cardiotoxicity, nephrotoxicity, hepatotoxicity, and neurotoxicity, remain significant challenges i…